eligibility_summary
Eligibility: NSCLC, no actionable mutations (except Substudy 02 after ≥1 matched targeted therapy), ECOG 0–1, measurable disease, adequate labs/organ function, contraception. SS01: Stage IV, PD‑L1 central, nonsq EGFR/ALK–, no prior systemic metastatic tx. SS02: Stage IV, prior targeted tx if actionable. SS03: Resectable stage II–IIIB(T3–4N2), planned (sleeve/bi)lobectomy, PD‑L1, nonsq EGFR/ALK–, untreated. Exclude: mixed histology, active 2nd cancer/autoimmune/pneumonitis/ILD/infection, SS01–02 active CNS mets or anticancer tx <4 wks, SS03 prior systemic/radiation or prior PD‑(L)1/CPI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 VELOCITY-Lung (NSCLC) tests novel combinations vs standard care across first-line metastatic, post-progression, and resectable settings. Agents and mechanisms: Zimberelimab (monoclonal antibody, anti–PD-1) restores T-cell activity, Domvanalimab (monoclonal antibody, anti-TIGIT) enhances T/NK cell activation, Etrumadenant (oral small-molecule, dual A2A/A2B adenosine receptor antagonist) blocks adenosine-driven immunosuppression, Sacituzumab govitecan-hziy (TROP-2–directed antibody-drug conjugate) delivers SN-38 (topoisomerase I inhibitor) to TROP-2+ tumor cells, Nivolumab (monoclonal antibody, anti–PD-1) comparator. Chemotherapy comparators: carboplatin/cisplatin (DNA crosslinkers), pemetrexed (antifolate), paclitaxel/nab-paclitaxel/docetaxel (taxane microtubule stabilizers). Targets: PD-1/PD-L1 and TIGIT/CD155 checkpoints on T and NK cells, adenosine A2A/A2B signaling in the tumor microenvironment, TROP-2 on tumor cells, DNA replication/repair and mitotic spindle.